Genentech Files Herceptin Supplemental Biologics License Application To FDA
Genentech said that the application is based on positive results from a Phase III study, known as ToGA, which showed that people who received Herceptin plus chemotherapy lived
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.